THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESISTANCE [IN-ARMOR]

Informations projet

IN-ARMOR

N° de convention de subvention: 101080889

DOI

10.3030/101080889

Date de signature de la CE 15 Mars 2023

Date de début 1 Mai 2023

Date de fin 30 Avril 2027

Financé au titre de

• Health

Coût total

€ 5 998 972,50

Contribution de l’UE

€ 5 998 972,25

Coordonné par

HASKOLI ISLANDS
Iceland

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (4)

Plan for Dissemination of Results (PDR), with Project Communication Plan (PCP)

Document containing the definition of the dissemination of results and communication plan and tools to be used during the life of the project. All possible dissemination routes for the obtained results will be identified and used during the whole course of the project.

Review of costs related to GI diseases. Elaboration of a scientific health-economics report with results from CEA based on current available studies on GI diseases.

The Document will consider data on the resources used in different treatment strategies of immunotherapies for GI diseases and the unit cost or price per resource and the main effects in terms of health gain. The analysis will capture the variability in the use and costs of the resources between multi-clinical units and in relation to patient status.

Health Technology Assessment structure definition.

Document presenting the basic structure of the HTA report, which will be continuously fulfilled as results of project are produced  and the information for these  parts of the HTA will be known: problem and new therapy description,  clinical effectiveness and safety,  costs and economic evaluation,  ethical aspects,  organisational aspects,  patients and social aspects. HTA report will present the projects outcomes and its effects on society, that may occur when a therapy is introduced, extended, or modified, with emphasis on the impacts that are direct but also unintended or indirect.

Policy Briefing I

On-page policy briefing to be shared with policy makers and their DGs. The document will list the achievements and results to date, pathways to impact and next steps to be taken.

Websites, patent fillings, videos etc. (1)

In-Armor public website and social channels

Document describing In-Armor webpage prepared in the first month of the project.

Publications

Peer reviewed articles (3)

Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections

Auteurs: Mohammad Faizan Bhat, Sonja Srdanović, Lotta-Riina Sundberg, Helga Kristín Einarsdóttir, Varpu Marjomäki, Frank J. Dekker
Publié dans: Drug Discovery Today, Numéro 29, 2024, ISSN 1359-6446
Éditeur: Elsevier BV
DOI: 10.1016/j.drudis.2024.104193

Histone Deacetylase 3‐Directed PROTACs Have Anti‐inflammatory Potential by Blocking Polarization of M0‐like into M1‐like Macrophages

Auteurs: Chunlong Zhao, Shipeng Chen, Deng Chen, Clàudia Río‐Bergé, Jianqiu Zhang, Petra E. Van Der Wouden, Toos Daemen, Frank J. Dekker
Publié dans: Angewandte Chemie International Edition, Numéro 62, 2023, ISSN 1433-7851
Éditeur: Wiley
DOI: 10.1002/anie.202310059

Host-directed therapies modulating innate immunity against infection in hematologic malignancies

Auteurs: Qiong Wang, Kristján Hermannsson, Egill Másson, Peter Bergman, Guðmundur Hrafn Guðmundsson
Publié dans: Blood Reviews, 2024, ISSN 0268-960X
Éditeur: Elsevier BV
DOI: 10.1016/j.blre.2024.101255